Poly Medicure cash flow

Latest FY26

Cash from operations: ₹241cr−0.2% on FY25
Capital spending: ₹308cr−5.1% on FY25
Free cash flow: −₹67.7cr−₹83.9 cr in FY25
Cash from financing: ₹20.2cr−97.9% on FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Changes in working capital
Adjustments to reconcile profit — non-cash items						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	—	116	81.4	63.9	57.2
	—	18.3	11.4	11.3	8.8
	—	−9.9	−12.9	−12.9	−5.9
	—	−0.9	−1.3	0.0	0.0
	—	−52.8	−37.7	−20.9	0.0
	—	7.4	1.2	0.0	0.0
	—	−11.7	−1.4	−1.8	−1.0
	—	3.6	−4.4	−0.2	4.0
	—	−37.2	−56.9	−12.4	−40.3
	—	−99.3	−84.8	−36.7	−28.8
	—	3.0	4.0	−5.6	−0.0
	—	−1.4	−0.8	−1.7	−0.1
	—	−34.6	−12.0	2.5	−1.1
	—	−3.1	0.2	0.1	0.1
	—	12.2	−10.3	3.8	3.8
	—	−9.9	8.5	13.5	5.8
	—	−25.1	−0.1	0.1	0.1
	—	26.2	−2.2	−4.5	9.8
	—	10.0	0.0	0.0	0.0
	—	2.5	0.1	−0.0	0.2
	—	7.9	0.6	0.3	0.6
Cash from operating activities
	416	422	447	342	236
	—	−79.4	−117	−1.4	13.1
	—	342	330	340	249
	—	102	89.0	74.3	57.9
	—	241	241	266	191
Cash from investing activities
	—	308	325	277	239
	—	2.6	0.7	1.9	0.1
	—	0.0	0.7	0.0	0.0
	—	0.0	882	15.0	−214
	—	482	0.0	35.5	−156
	—	419	0.0	0.0	0.0
	—	4.0	2.4	0.5	0.8
	—	13.8	12.5	13.2	1.6
	—	−225	−1,191	−241	−179
Cash from financing activities
	—	0.0	1,000	0.3	0.4
	—	0.3	0.4	0.0	0.0
	—	74.6	10.4	0.0	0.0
	—	0.0	0.0	−21.1	−21.0
	—	3.3	2.2	1.8	1.4
	—	16.0	10.7	11.0	8.5
	—	35.4	30.3	28.7	24.0
	—	0.0	−14.7	0.0	0.0
	—	20.2	953	−20.2	−12.5
	—	35.5	2.8	5.0	−0.7
	—	1.4	0.0	0.0	0.0
	—	36.8	2.8	5.0	−0.7
	—	—	8.7	12.1	7.1
Reference items
	461	442	453	358	265
	23.1%	23.6%	27.1%	26.0%	23.8%
	−67.7	−67.7	−83.9	−10.9	−48.4
	—	80.3	−87.1	1.8	—
	−₹6.68	−₹6.68	−₹8.28	−₹1.08	−₹4.78
	—	0.75×	0.71×	1.03×	1.06×
	—	102	89.0	74.3	57.9
	—	16.0	10.7	11.0	8.5

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

POLYMED₹1,461.90

Poly Medicure Ltd.

· Pharma & Health

₹ CrorePeersPFIZER RAINBOW ONESOURCE KIMS JUBLPHARMA VIJAYA INDGN GRANULESMcap ₹14,818 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation	57.2	63.9	81.4	115.5	—
+ Finance Costs	8.8	11.3	11.4	18.3	—
+ Interest Income	-5.9	-12.9	-12.9	-9.9	—
+ Dividend Income	0.0	0.0	-1.3	-0.9	—
+ Fair Value (Gains) / Losses	0.0	-20.9	-37.7	-52.8	—
+ Share-based Payments	0.0	0.0	1.2	7.4	—
+ Unrealised FX (Gain) / Loss	-1.0	-1.8	-1.4	-11.7	—
+ Other Non-cash Items	4.0	-0.2	-4.4	3.6	—
Changes in Working Capital
+ Inventories	-40.3	-12.4	-56.9	-37.2	—
+ Trade Receivables — Current	-28.8	-36.7	-84.8	-99.3	—
+ Other Financial Assets — Current	-0.0	-5.6	4.0	3.0	—
+ Other Financial Assets — Non-current	-0.1	-1.7	-0.8	-1.4	—
+ Other Current Assets	-1.1	2.5	-12.0	-34.6	—
+ Other Non-current Assets	0.1	0.1	0.2	-3.1	—
+ Trade Payables — Current	3.8	3.8	-10.3	12.2	—
+ Other Financial Liabilities — Current	5.8	13.5	8.5	-9.9	—
+ Other Financial Liabilities — Non-current	0.1	0.1	-0.1	-25.1	—
+ Other Current Liabilities	9.8	-4.5	-2.2	26.2	—
+ Other Non-current Liabilities	0.0	0.0	0.0	10.0	—
+ Provisions — Current	0.2	-0.0	0.1	2.5	—
+ Provisions — Non-current	0.6	0.3	0.6	7.9	—
Cash from Operating Activities
Profit Before Tax (per I/S)	235.6	341.7	447.3	421.8	415.9
+ Total Adjustments (incl. Working Capital)	13.1	-1.4	-117.2	-79.4	—
Cash from Operations (pre-tax)	248.7	340.4	330.1	342.4	—
+ Income Taxes Paid	57.9	74.3	89.0	101.7	—
Cash from Operating Activities	190.8	266.1	241.1	240.7	—
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)	239.3	277.0	325.0	308.4	—
+ Disp of Fixed Assets	0.1	1.9	0.7	2.6	—
+ Disp of Investment Property	0.0	0.0	0.7	0.0	—
+ Acq of Other Long-term Assets	-214.0	15.0	882.5	0.0	—
+ Disp of Other Long-term Assets	-156.2	35.5	0.0	481.8	—
+ Acq of Subsidiaries / Businesses (net)	0.0	0.0	0.0	419.2	—
+ Dividends Received — Investing	0.8	0.5	2.4	4.0	—
+ Interest Received — Investing	1.6	13.2	12.5	13.8	—
Cash from Investing Activities	-179.0	-240.9	-1,191.2	-225.4	—
Cash from Financing Activities
+ Proceeds from Issue of Shares	0.4	0.3	1,000.0	0.0	—
+ Proceeds from Exercise of Stock Options	0.0	0.0	0.4	0.3	—
+ Proceeds from Borrowings	0.0	0.0	10.4	74.6	—
+ Repayment of Borrowings	-21.0	-21.1	0.0	0.0	—
+ Payment of Lease Liabilities	1.4	1.8	2.2	3.3	—
+ Interest Paid	8.5	11.0	10.7	16.0	—
+ Dividends Paid	24.0	28.7	30.3	35.4	—
+ Other Inflows / (Outflows) — Financing	0.0	0.0	-14.7	0.0	—
Cash from Financing Activities	-12.5	-20.2	952.9	20.2	—
Net Changes in Cash (pre-FX)	-0.7	5.0	2.8	35.5	—
+ Effect of FX Rate Changes on Cash	0.0	0.0	0.0	1.4	—
Net Changes in Cash	-0.7	5.0	2.8	36.8	—
Closing Cash	7.1	12.1	8.7	—	—
Reference Items
EBITDA	265.4	358.2	452.8	442.3	461.4
EBITDA Margin %	23.80	26.04	27.12	23.59	23.10
Free Cash Flow (CFO − Capex)	-48.4	-10.9	-83.9	-67.7	-67.7
Free Cash Flow to Equity	—	1.8	-87.1	80.3	—
Free Cash Flow per Basic Share	-4.78	-1.08	-8.28	-6.68	-6.68
Cash Flow to Net Income	1.06	1.03	0.71	0.75	—
Cash Paid for Taxes	57.9	74.3	89.0	101.7	—
Cash Paid for Interest	8.5	11.0	10.7	16.0	—

As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.